Technical Analysis for NUVL - Nuvalent, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 72.49 | 2.60% | 1.84 |
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Above Upper BB | Strength | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Up 5 Days in a Row | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| New Uptrend | Bullish | 2.60% | |
| Stochastic Reached Overbought | Strength | 2.60% | |
| Multiple of Ten Bullish | Other | 2.60% |
| Alert | Time |
|---|---|
| Up 3% | about 14 hours ago |
| Rose Above Previous Day's High | about 15 hours ago |
| 60 Minute Opening Range Breakout | about 15 hours ago |
| Up 2% | about 15 hours ago |
| Possible NR7 | about 15 hours ago |
Get a Trading Assistant
- Earnings date: 05/09/2024
Nuvalent, Inc. Description
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Organic Compounds Chemical Compounds Tyrosine Kinase Receptors Preclinical Stage Biopharmaceutical Anaplastic Lymphoma Kinase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 89.39 |
| 52 Week Low | 37.13 |
| Average Volume | 512,539 |
| 200-Day Moving Average | 63.65 |
| 50-Day Moving Average | 75.61 |
| 20-Day Moving Average | 67.07 |
| 10-Day Moving Average | 67.50 |
| Average True Range | 2.92 |
| RSI (14) | 56.71 |
| ADX | 31.33 |
| +DI | 24.82 |
| -DI | 21.65 |
| Chandelier Exit (Long, 3 ATRs) | 66.47 |
| Chandelier Exit (Short, 3 ATRs) | 70.55 |
| Upper Bollinger Bands | 72.15 |
| Lower Bollinger Band | 61.99 |
| Percent B (%b) | 1.03 |
| BandWidth | 15.15 |
| MACD Line | -1.38 |
| MACD Signal Line | -2.62 |
| MACD Histogram | 1.2391 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 75.99 | ||||
| Resistance 3 (R3) | 75.86 | 74.58 | 75.40 | ||
| Resistance 2 (R2) | 74.58 | 73.69 | 74.64 | 75.21 | |
| Resistance 1 (R1) | 73.53 | 73.14 | 74.06 | 73.66 | 75.01 |
| Pivot Point | 72.25 | 72.25 | 72.51 | 72.31 | 72.25 |
| Support 1 (S1) | 71.20 | 71.36 | 71.73 | 71.33 | 69.97 |
| Support 2 (S2) | 69.92 | 70.81 | 69.98 | 69.77 | |
| Support 3 (S3) | 68.87 | 69.92 | 69.58 | ||
| Support 4 (S4) | 69.00 |
